Comments
German generic drugmaker Stada struck an alliance with Hetero Drugs Ltd to gain access to active ingredients for cancer drugs, Stada said on Thursday.
As part of the agreement in principle, with details yet to be hammered out, Stada will get exclusive marketing rights in Europe for generic oncology drugs developed and produced by Hetero. Stada will also get a sub-licence in further regions outside India and the United States.
The alliance covers cancer drugs that will lose patent protection between 2016 and 2020 and Stada will decide at a later stage whether Hetero compounds will also go its existing oncology drugs, Stada Chief Executive Hartmut Retzlaff said at a press conference.
Financial terms were not provided.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.